Arash Naghavi
@Naghavi_MD
Followers
129
Following
20
Media
22
Statuses
60
Joined August 2012
How can we better manage unresectable soft tissue sarcoma patients? A privilege to speak at #ASTRO25 and a great educational session with Prof. Indelicato, @Naghavi_MD and Acharya, about historical results and current development axes. @CLCCLeonBerard
1
1
3
How can we better manage unresected soft tissue sarcomas? Arash Naghavi, MD (@Naghavi_MD), discusses novel photon therapy techniques including the HARD (Hypofrartionated Accelerated Radiation Dose) method during his oral presentation at the @ASTRO_org Annual Meeting.
1
1
1
An innovative approach that had a real impact on our prostate cancer patient’s QOL. PAE also converted 52% of patients initially contraindicated for brachytherapy/SBRT without an impact on local control! Amazing work @VaseemKhatri ! @MoffittNews
HOT OFF THE PRESS! Neoadjuvant PAE prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation - https://t.co/uk9rtTBJuO
@MoffittNews @MoffittRadOnc @KOSJ12 @gdgrass @VaseemKhatri @ctRO_journal
2
2
14
HOT OFF THE PRESS! Neoadjuvant PAE prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation - https://t.co/uk9rtTBJuO
@MoffittNews @MoffittRadOnc @KOSJ12 @gdgrass @VaseemKhatri @ctRO_journal
ctro.science
Prostate cancer is the second most common malignancy in men, with 1.2 million new cases each year, and radiation therapy (RT) is standard of care for all National Comprehensive Cancer Network (NCCN)...
7
23
68
hot off the press - our @MoffittNews #multiD approach to #PAE in the setting of prostate cancer!! let’s go! 💪🏾💪🏾 @KOSJ12 @gdgrass @JulioPowSangMD @MoffittRadOnc @RishiA_MD #irad
5
20
100
Thank you for the feature @MoffittNews ! Looking forward to being more active on X.
#FollowFriday Meet Michaela Druta, MD (@MihaelaDruta), Vice Chair of the Sarcoma Department. She specializes in developing targeted therapies and immunotherapies for sarcoma, focusing on translational science and the biology of the disease. Be sure to give her a follow!
0
2
12
It’s an honor to work with such an amazing physician! The Moffitt Sarcoma team are making a real impact on the field!
Thank you for the feature @MoffittNews ! Looking forward to being more active on X.
0
2
8
Utilizing the HARD approach, we showed a 2 fold increase in 3y LC (96% vs 48%), along with a PFS benefit for non-metastatic patients! @MoffittRadOnc @MoffittNews
#GoHardAtSoftTissueSarcoma
https://t.co/mV7BzeHu2X
thegreenjournal.com
Soft tissue sarcomas (STS) are rare malignant tumors arising from mesenchymal and connective tissues marked by significant heterogeneity and morbidity[1–3]. Surgery is the primary curative treatment,...
0
3
12
Congratulations to @Naghavi_MD, @JMBryantMD, et al. for their HARD work and creating innovative and sophisticated solutions for patients with unresected soft-tissue sarcoma! Hypofractionated accelerated radiation dose-painting (HARD) improves o...
1
7
18
Utilizing the HARD technique for Unresected sarcomas showed a 2-fold increase in 3y LRC (96% v 48%), when compared to standard fractionated RT. Congrats to @JMBryantMD for acceptance in @RO_GreenJournal. @MoffittRadOnc @MoffittNews #greenjournal @RadiotherapyOn1 @QuadShotNews
Thanks @QuadShotNews for highlighting the HARD work by @JMBryantMD and @MNMillsMD
https://t.co/3seSSxsPMz
#GoingHARDatSoftTissueSarcoma
@MoffittNews
@MoffittRadOnc
2
9
20
Thank you John! HEAT would not be possible without the support of the sarcoma team, our radiation department, and our patients! We continue our mission to the prevention and cure of cancer through innovation and personalized medicine! @MoffittNews @MoffittRadOnc
So proud of my friend and colleague @Naghavi_MD for his innovative HEAT trial and the exciting results today at @ctosociety meeting. He’s developed such a thoughtful RT approach to address the heterogeneity of STS. @MoffittNews @MoffittRadOnc
0
0
6
Another outstanding talk by @MihaelaDruta from our #sarcoma team on the correlative work from SPEARHEAD-1 at the @ctosociety annual meeting. @MoffittNews @Adaptimmune
0
3
16
Thank you @IJROBP for showcasing our HARD take on unresected Sarcomas! Great opportunity collaborating with @VictoriaRizkMD! https://t.co/k1pXlBlaw3
1
8
24
Utilizing Genomics and Radiomics to escalate radiotherapy in Sarcoma (HEAT), will offer insight to the innate and heterogenous radiosensitivity of STS, bringing us a step closer to a personalized treatment approach for this disease. @MoffittNews
https://t.co/DMw9dCLIh0
bmccancer.biomedcentral.com
Background Soft tissue sarcomas (STS), have significant inter- and intra-tumoral heterogeneity, with poor response to standard neoadjuvant radiotherapy (RT). Achieving a favorable pathologic response...
1
5
16
Getting Personal: Optimizing RT Dosing Strategies for Improved Outcomes Learn more ➡️ https://t.co/VNHx98olYL
@MoffittNews @Naghavi_MD
#RadOnc #RadOncNews #RadOncEd #CancerTreatment #RadiationOncology #Oncology
1
15
26
🎙 HARD RT shows promising locoregional control with acceptable tox for unresected STS❗️❗️@OncoAlert @ad 📌Retro study- HARD RT applied to unresected STS (2019-2022), 27 👥 Dose Variation:HR: 3.0 Gy, IR: 2.5 Gy, LR: 2.0-2.3 Gy per fx 📊RESULTs -FU Median 33.4 m -100% LC at 3 y
0
26
42
Dr. John Michael Bryant (@JMbryantMD) joined us at the Moffitt booth to discuss how hypofractionated accelerated radiation dose-painting (HARD) improves local control in unresected soft-tissue sarcoma. #ASTRO23. Learn more ➡️ https://t.co/3q1OByMIuK
0
2
16
Key findings: HARD regimen proves to be a safe method for dose escalation in STS, achieving durable 3-year locoregional control without severe toxicity. #SarcomaResearch #InnovativeTreatment
@Naghavi_MD @RadOnc_MM @LiveringhouseCL @MoffittRadOnc @MoffittResearch
1
1
4